Mercy BioAnalytics Hires Seasoned Diagnostics Executive as Chief Commercial Officer to Drive Market Launch

New updates have been reported about Mercy BioAnalytics.

Mercy BioAnalytics has appointed Darrin Crisitello as Chief Commercial Officer, a move that signals the company is preparing to transition from development to commercial scale in early cancer detection. Crisitello will oversee global commercial strategy, including go-to-market planning, partnerships, and revenue generation as Mercy advances its Mercy Halo™ liquid biopsy platform and oncology test portfolio toward broader clinical adoption, initially focused on early detection of ovarian and lung cancers. CEO Dawn Mattoon said his mix of strategic vision and operational experience in launching breakthrough diagnostics and building commercial organizations is expected to be central to expanding access to Mercy’s tests and executing its growth strategy. The company’s platform uses biomarker co-localization on blood-based extracellular vesicles to detect unique cancer signatures, aiming to identify cancers at earlier, more treatable stages and thereby improve outcomes and reduce downstream treatment costs.

Cr sitello brings more than two decades of commercial leadership in diagnostics, life sciences, and health-tech, with a track record that is directly relevant to Mercy’s scaling needs. He previously served as Chief Commercial Officer at Quanterix, where he led commercialization of ultra-sensitive biomarker detection platforms for neurology and oncology, and before that held senior roles at Natera, helping launch the Panorama non-invasive prenatal test and supporting Natera’s 2015 IPO, as well as at Color Health, where he drove early commercial growth and market expansion. His background indicates that Mercy is likely positioning itself for aggressive market entry, potential strategic partnerships, and future capital-raising or exit options once commercial traction is demonstrated. Crisitello, who holds a BS in Biology and Chemistry and an MBA, highlighted Mercy’s science as having the potential to change how cancer is detected and managed and emphasized a focus on bringing these innovations to clinicians and patients at scale. For executives and investors, the hire underscores that Mercy is moving into a commercialization phase where execution on sales, market access, and health system partnerships will be critical to value creation.